Cantor Fitzgerald Issues Negative Forecast for BMY Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Stock analysts at Cantor Fitzgerald reduced their FY2026 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a research report issued on Friday, October 31st. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will post earnings of $5.74 per share for the year, down from their previous forecast of $6.08. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the previous year, the business earned $1.80 EPS. Bristol Myers Squibb’s revenue for the quarter was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS.

Several other equities analysts have also weighed in on BMY. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Daiwa America cut Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, October 13th. Finally, Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fourteen have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $57.23.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $46.10 on Monday. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $63.33. The business has a 50-day moving average price of $45.34 and a 200 day moving average price of $46.78. The firm has a market cap of $93.82 billion, a PE ratio of 18.59, a P/E/G ratio of 2.23 and a beta of 0.33.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.4%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb’s payout ratio is currently 83.78%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares in the company, valued at $7,922,048.07. The trade was a 25.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.09% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Bristol Myers Squibb during the 1st quarter worth approximately $31,000. Trifecta Capital Advisors LLC acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Accent Capital Management LLC acquired a new position in shares of Bristol Myers Squibb during the 1st quarter worth approximately $33,000. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $25,000. Finally, CBIZ Investment Advisory Services LLC raised its position in shares of Bristol Myers Squibb by 66.0% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 231 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.